Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

GSK plc American Depositary Shares (Each representing two Ordinary Shares) (NY:GSK)

51.27 -0.27 (-0.53%)
Delayed Quote Updated: 1:12 PM EST, Nov 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about GSK plc American Depositary Shares (Each representing two Ordinary Shares)

< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
46 47 Next >
News headline image
Law Offices of Howard G. Smith Encourages GSK plc. (GSK) Investors To Inquire About Securities Fraud Class Action
From Law Offices of Howard G. Smith
Via Business Wire
News headline image
GSK PLC Stockholder Notice: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Lawsuit Against GSK
From Robbins LLP
Via GlobeNewswire
News headline image
GSK Investors Have Opportunity to Lead GSK plc Securities Fraud Lawsuit with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
News headline image
Bear Of The Day: Gsk Plc ↗
GSK PLC is a Zacks Rank #5 (Strong Sell) after the company beat the Zacks Consensus Estimate when the last reported. 
Via Talk Markets
Topics Stocks / Equities
News headline image
Earnings Scheduled For February 5, 2025 ↗
 
Via Benzinga
News headline image
Securities Fraud Investigation Into GSK plc. (GSK) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm
From Glancy Prongay & Murray LLP
Via Business Wire
News headline image
GSK plc. (GSK) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
From Law Offices of Howard G. Smith
Via Business Wire
News headline image
Rosen Law Firm Urges GSK plc (NYSE: GSK) Investors with Large Losses to Contact the Firm for Information About Their Rights
From The Rosen Law Firm, P.A.
Via Business Wire
News headline image
Securities Fraud Investigation Into GSK plc. (GSK) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
From The Law Offices of Frank R. Cruz
Via Business Wire
News headline image
Electronic Arts Posts Upbeat Earnings, Joins Mattel, Johnson Controls, Mueller Water Products And Other Big Stocks Moving Higher On Wednesday ↗
 
Via Benzinga
News headline image
GSK Q4 Earnings: Revenue And EPS Beat, Initiates $2.5 Billion Stock Buyback, Raises Long-Term Annual Sales Forecast To Over $50 Billion ↗
GSK's Q4 sales hit $10.40 billion, topping estimates. Specialty Medicines grew 14%, while vaccines declined. The company announced a $2.5 billion share buyback plan. 
Via Benzinga
News headline image
RFK Jr. Clears A Key Hurdle To Head Up HHS. Why His Nomination Is A Biotech Black Box. ↗
RFK Jr. cleared a key hurdle Tuesday after the Senate Finance Committee voted along party lines in favor of his nomination. 
Via Investor's Business Daily
News headline image
The RFK Jr. Effect: Biotech Stocks Brace For 'Games' In Senate Hearings ↗
The Senate will meet Wednesday to start the confirmation hearing process for Robert F. Kennedy Jr. 
Via Investor's Business Daily
News headline image
Moderna, Pfizer Surge Amid CDC-WHO Split And Bird Flu; RFK Jr. Nomination Looms — A Recipe For The Perfect Storm? ↗
The Centers for Disease Control and Prevention abruptly ordered its staff to cease all collaboration with the World Health Organization on Monday, marking a dramatic acceleration of President Donald... 
Via Benzinga
Topics Government
News headline image
Trump Administration Halts All Communications From The Centers For Disease Control As Bird Flu Spreads ↗
As the bird flu virus continues to spread through the United States, the Trump administration on Tuesday ordered all communications from the Centers for Disease Control and Prevention to stop. 
Via Benzinga
Topics Government
News headline image
Demand for Advanced Pancreatic Cancer Treatments at All Time High as Promising Options Come into Focus
From FN Media Group LLC
Via GlobeNewswire
News headline image
After a Reset Year, Is Moderna Stock Poised for a Comeback?
Moderna had a rough 2024 and is starting 2025 with lowered forecasts, but is focused on getting 10 FDA approvals in the next three years. Is now time to buy? 
Via MarketBeat
News headline image
Bird Flu Update: First Commercial Case In Georgia, Moderna Receives $590 Million To Develop Vaccine ↗
According to the latest data from the Centers for Disease Control, the current bird flu outbreak has caused 67 human cases of bird flu in the U.S. and one death associated with the virus. 
Via Benzinga
News headline image
Europe Drug Regulator Expands GSK's Jemperli/Chemo Combo To Adult Patients With Advanced Endometrial Cancer ↗
GSK's Jemperli wins EU approval for broader use in advanced endometrial cancer, showing improved survival and significant trial results. 
Via Benzinga
News headline image
Deal Dispatch: Biden Punts TikTok Ban To Trump, Plus Another Legacy Retailer Goes Bankrupt ↗
Deal opportunities abound: KKR & Co.'s stake in Maya; DuPont's electronics business; Ingevity's North Charleston site; and S&W Seed Company. 
Via Benzinga
Topics Government
News headline image
Popular Ozempic, Wegovy Selected For Next Round Of Medicare Drug Price Negotiations ↗
HHS adds 15 drugs to Medicare Part D price negotiations, targeting cost reductions under the Inflation Reduction Act. New prices aim to save billions by 2027. 
Via Benzinga
Topics Economy
News headline image
Bird Flu Raising Red Flags Among Health Officials, CDC Urges Faster Testing ↗
The CDC issued a health advisory Thursday recommending that hospitalized patients who have tested positive for influenza be tested for the bird flu virus within 24 hours. 
Via Benzinga
News headline image
Will GSK’s Seasonal Strength And Oncology Focus Drive Gains? ↗
A look at GSK’s long-term price action reveals critical levels on the monthly chart. 
Via Talk Markets
Topics Stocks / Equities
News headline image
GSK Highlights New Approvals, Vaccine Momentum At JPMorgan Healthcare Conference ↗
GSK plans five new product approvals by 2025, highlights strong specialty growth, and acquires IDRx for $1 billion to expand its oncology portfolio. 
Via Benzinga
News headline image
Moderna Has Lost 94% Of Its Value Over Four Years. Is It A Sell? ↗
Shares hit another skid on Jan. 13 when the company cut its guidance for 2024 and 2025. 
Via Investor's Business Daily
News headline image
GSK To Buy US-Based Stomach Cancer Drug Developer For Over $1 Billion ↗
GSK's $1 billion acquisition of IDRx includes IDRX-42, a precision therapy for GIST. Phase 1/1b trial shows 53% ORR in early treatment stages. 
Via Benzinga
News headline image
GSK Enters Agreement to Acquire IDRx, Inc.
From GSK plc and IDRx, Inc.
Via Business Wire
News headline image
Why CureVac (CVAC) Shares Are Volatile ↗
CureVac shares have been volatile over the past week, gaining some 25%. The stock has seen increased trading volume following the U.S.'s first human death from H5N1 bird flu. 
Via Benzinga
News headline image
Bird Flu Sparks Vaccine Stock Surge: ETFs To Watch As H5N1 Outbreak Intensifies ↗
Bird flu has severely impacted poultry farms and cattle herds across 16 states, marking the worst outbreak of its kind. 
Via Benzinga
Topics ETFs
News headline image
Pfizer And GSK's RSV Vaccines Safety Labels Updated, FDA Adds Warning For Rare Neurological Disorder ↗
FDA updates safety labels for Pfizer's Abrysvo and GSK's Arexvy RSV vaccines, citing increased Guillain-Barré syndrome risk. Study estimates 7-9 excess GBS cases per million doses. 
Via Benzinga
< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
46 47 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.